Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 950

1.

Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial.

Kim L, Liebowitz D, Lin K, Kasparek K, Pasetti MF, Garg SJ, Gottlieb K, Trager G, Tucker SN.

JCI Insight. 2018 Jul 12;3(13). pii: 121077. doi: 10.1172/jci.insight.121077. [Epub ahead of print]

2.

Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails.

Li H, Shi FH, Huang SY, Zhang SG, Gu ZC, Wei JF.

Medicine (Baltimore). 2018 Jul;97(28):e11507. doi: 10.1097/MD.0000000000011507.

3.

Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women.

Joag V, Sivro A, Yende-Zuma N, Imam H, Samsunder N, Abdool Karim Q, Abdool Karim S, McKinnon L, Kaul R.

PLoS One. 2018 Jul 9;13(7):e0200359. doi: 10.1371/journal.pone.0200359. eCollection 2018.

4.

PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.

Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S.

Expert Opin Investig Drugs. 2018 Jul 16:1-7. doi: 10.1080/13543784.2018.1494722. [Epub ahead of print]

PMID:
29985060
5.

Core-shell nanoparticles for targeted and combination antiretroviral activity in gut-homing T cells.

Cao S, Jiang Y, Zhang H, Kondza N, Woodrow KA.

Nanomedicine. 2018 Jun 28. pii: S1549-9634(18)30479-9. doi: 10.1016/j.nano.2018.06.005. [Epub ahead of print]

PMID:
29964219
6.

Clindamycin Administration Increases the Incidence of Collagen-Induced Arthritis in Mice Through the Prolonged Impact of Gut Immunity.

Yang S, Chen H, Wei B, Xiang M, Hu Z, Peng Z, Lin H, Sun J.

Inflammation. 2018 Jun 27. doi: 10.1007/s10753-018-0833-4. [Epub ahead of print]

PMID:
29951875
7.

Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.

Scribano ML.

World J Gastroenterol. 2018 Jun 21;24(23):2457-2467. doi: 10.3748/wjg.v24.i23.2457. Review.

8.

Development of Endocyclic Control Elements for Peptide Macrocycles.

Appavoo SD, Kaji T, Frost JR, Scully CCG, Yudin AK.

J Am Chem Soc. 2018 Jul 18;140(28):8763-8770. doi: 10.1021/jacs.8b04412. Epub 2018 Jul 3.

PMID:
29920073
9.

AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation.

Ichikawa R, Lamb CA, Eastham-Anderson J, Scherl A, Raffals L, Faubion WA, Bennett MR, Long AK, Mansfield JC, Kirby JA, Keir ME.

J Crohns Colitis. 2018 Jun 15. doi: 10.1093/ecco-jcc/jjy084. [Epub ahead of print]

PMID:
29912405
10.

Dietary Red Raspberry Reduces Colorectal Inflammation and Carcinogenic Risk in Mice with Dextran Sulfate Sodium-Induced Colitis.

Bibi S, Du M, Zhu MJ.

J Nutr. 2018 Apr 20. doi: 10.1093/jn/nxy007. [Epub ahead of print]

PMID:
29897487
11.

The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation.

Nhu QM, Chiao H, Moawad FJ, Bao F, Konijeti GG.

Am J Gastroenterol. 2018 Jun 12. doi: 10.1038/s41395-018-0145-1. [Epub ahead of print] No abstract available.

PMID:
29895980
12.

Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics.

Bridgewood C, Watad A, Cuthbert RJ, McGonagle D.

Curr Opin Rheumatol. 2018 Jun 9. doi: 10.1097/BOR.0000000000000529. [Epub ahead of print]

PMID:
29889692
13.

MAdCAM costimulation through Integrin-α4β7 promotes HIV replication.

Nawaz F, Goes LR, Ray JC, Olowojesiku R, Sajani A, Ansari AA, Perrone I, Hiatt J, Van Ryk D, Wei D, Waliszewski M, Soares MA, Jelicic K, Connors M, Migueles SA, Martinelli E, Villinger F, Cicala C, Fauci AS, Arthos J.

Mucosal Immunol. 2018 Jun 6. doi: 10.1038/s41385-018-0044-1. [Epub ahead of print]

PMID:
29875402
14.

Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.

Paul S, Williet N, Di Bernado T, Berger AE, Boschetti G, Filippi J, Del Tedesco E, Nancey S, Flourie B, Roblin X.

J Crohns Colitis. 2018 May 31. doi: 10.1093/ecco-jcc/jjy077. [Epub ahead of print]

PMID:
29860366
15.

Rapid response to vedolizumab therapy in biologic-naïve patients with inflammatory bowel diseases.

Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, Colombel JF.

Clin Gastroenterol Hepatol. 2018 May 29. pii: S1542-3565(18)30558-5. doi: 10.1016/j.cgh.2018.05.026. [Epub ahead of print]

16.

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.

Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, Hirschmann S, Hildner K, Waldner MJ, Mudter J, Hartmann A, Grützmann R, Neufert C, Münster T, Neurath MF, Atreya R.

Gut. 2018 May 30. pii: gutjnl-2017-315671. doi: 10.1136/gutjnl-2017-315671. [Epub ahead of print]

17.

Retinoic acid elicits a coordinated expression of gut homing markers on T lymphocytes of Zambian men receiving oral Vivotif, but not Rotarix, Dukoral or OPVERO vaccines.

Mwanza-Lisulo M, Chomba MS, Chama M, Besa EC, Funjika E, Zyambo K, Banda R, Imikendu M, Sianongo S, Hancock REW, Lee A, Chilengi R, Stagg AJ, Namangala B, Kelly PM.

Vaccine. 2018 Jun 27;36(28):4134-4141. doi: 10.1016/j.vaccine.2018.04.083. Epub 2018 May 22.

18.

Integrin α4β7 switches its ligand specificity via distinct conformer-specific activation.

Wang S, Wu C, Zhang Y, Zhong Q, Sun H, Cao W, Ge G, Li G, Zhang XF, Chen J.

J Cell Biol. 2018 May 22. pii: jcb.201710022. doi: 10.1083/jcb.201710022. [Epub ahead of print]

PMID:
29789438
19.

Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.

De Vos M, Dhooghe B, Vermeire S, Louis E, Mana F, Elewaut A, Bossuyt P, Baert F, Reenaers C, Van Gossum M, Macken E, Ferrante M, Hindryckx P, Dewit O, Holvoet T, Franchimont D; Belgian Inflammatory Bowel Disease Research and Development (BIRD).

United European Gastroenterol J. 2018 Apr;6(3):439-445. doi: 10.1177/2050640617722310. Epub 2017 Jul 26.

20.

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions.

Ward MG, Sparrow MP, Roblin X.

Therap Adv Gastroenterol. 2018 May 8;11:1756284818772786. doi: 10.1177/1756284818772786. eCollection 2018. Review.

Supplemental Content

Loading ...
Support Center